Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Pulse Biosciences Inc (NASDAQ: PLSE) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Pulse Biosciences Inc (NASDAQ: PLSE)  concerning whether a series of statements by Pulse Biosciences Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 11, 2017, Pulse Biosciences revealed that it withdrew its application to the FDA for 510(k) clearance of its PulseTx System. Additionally, Pulse Biosciences revealed that the withdrawal was the result of “the FDA’s appropriate request for additional data that could not be provided within the Agency’s 90-day review period that would have otherwise ended on September 10, 2017.”

Following this news, NASDAQ: PLSE dropped more than 14% during intraday trading on September 11, 2017.

Based in Burlingame, California, and founded in 2014 Pulse Biosciences Inc a medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology.

If you purchased shares of Pulse Biosciences Inc (NASDAQ: PLSE) on or before September 11, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185